SB 218078 |
رقم الكتالوجGC11022 |
SB 218078 هو مثبط كيناز 1 (Chk1) فعال ، وانتقائي ، منافس لـ ATP ونفاذ الخلية ، والذي يمنع فسفرة Chk1 لـ \u200b\u200bcdc25C مع IC50 من 15 نانومتر. SB 218078 هو أقل فعالية في تثبيط Cdc2 (IC50 من 250 نانومتر) و PKC (IC50 من 1000 نانومتر). SB 218078 يسبب موت الخلايا المبرمج عن طريق تلف الحمض النووي وتوقف دورة الخلية.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 135897-06-2
Sample solution is provided at 25 µL, 10mM.
Targets:Chk1, cdc2 and PKC
IC50:15, 250 and 1000 nM for Chk1, cdc2 and PKC respectively
SB 218078 is a potent inhibitor of checkpoint kinase 1, with the IC50 values of 15, 250 and 1000 nM for Chk1, cdc2 and PKC, respectively.
In Vitro: An in vitro kinase assay found that SB 218078 could potently inhibit the phosphorylation of Chk1, with the IC50 of 15 nM. In Hela cells, SB 218078 could cause complete abrogation of G2 cell cycle arrest induced by topotecan, with the minimum concentration of 2.5 μM [1]. Besides, 15 nM SB 218078 could effectively inhibit NKG2D ligand upregulation induced by aphidicolin in fibroblasts [2]. Furthermore, treated GM02188 cells with 2.5 μM SB 218078 could inhibit the formation of HU-induced 53bp1 foci and prevent recovery from replication fork stalling induced by APH [3].
In Vivo: In Myc-induced lymphomas mouse model, treatment with SB 218078 with the dose of 5 mg/kg could promote a strong increase of γ-H2AX and apoptosis throughout the lymphoma, while having no effect on a healthy spleen [4].
Clinical trial: No data available recently
References:
[1] Jackson J R, Gilmartin A G, Imburgia C S, et al. An Indolocarbazole Inhibitor of Human Checkpoint Kinase (Chk1) Abrogates Cell Cycle Arrest Caused by DNA Damage[J]. Cancer Research, 2000, 60(3): 566-572.
[2] Gasser S, Orsulic S, Brown E J, et al. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor[J]. Nature, 2005, 436(7054): 1186-1190.
[3] Alderton G K, Galbiati L, Griffith E, et al. Regulation of mitotic entry by microcephalin and its overlap with ATR signalling[J]. Nature Cell Biology, 2006, 8(7): 725-733.
[4] Murga M, Campaner S, Lopez-Contreras A J, et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors[J]. Nature structural & molecular biology, 2011, 18(12): 1331-1335.
Cas No. | 135897-06-2 | SDF | |
Chemical Name | 9,10,11,12-tetrahydro-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1,3(2H)-dione | ||
Canonical SMILES | O=C(NC1=O)C2=C1C3=C4C5=C2C6=C(C=CC=C6)N5C7OC(CC7)N4C8=C3C=CC=C8 | ||
Formula | C24H15N3O3 | M.Wt | 393.4 |
الذوبان | ≤5mg/ml in DMSO;5mg/ml in dimethyl formamide | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 2.5419 mL | 12.7097 mL | 25.4194 mL |
5 mM | 0.5084 mL | 2.5419 mL | 5.0839 mL |
10 mM | 0.2542 mL | 1.271 mL | 2.5419 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5
(Based on Reviews and 15 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *